Vigil Neuroscience Inc
VIGL8.050USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
375.71MMarket Cap
LossP/E TTM
More Details of Vigil Neuroscience Inc Company
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Vigil Neuroscience Inc Info
Ticker SymbolVIGL
Company nameVigil Neuroscience Inc
IPO dateJan 07, 2022
CEO- -
Number of employees69
Security typeOrdinary Share
Fiscal year-endJan 07
Address100 Forge Road
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone18572544445
Websitehttps://www.vigilneuro.com/
Ticker SymbolVIGL
IPO dateJan 07, 2022
CEO- -
Company Executives of Vigil Neuroscience Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Gray, Ph.D.
Dr. David Gray, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Gray, Ph.D.
Dr. David Gray, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Beryl Capital Management, LLC
9.66%
Amgen Inc
6.72%
Glazer Capital, LLC
6.31%
Oddo BHF Asset Management S.A.S
4.82%
Gabelli Funds, LLC
4.46%
Other
68.02%
Shareholders
Shareholders
Proportion
Beryl Capital Management, LLC
9.66%
Amgen Inc
6.72%
Glazer Capital, LLC
6.31%
Oddo BHF Asset Management S.A.S
4.82%
Gabelli Funds, LLC
4.46%
Other
68.02%
Shareholder Types
Shareholders
Proportion
Corporation
6.72%
Venture Capital
3.48%
Individual Investor
0.03%
Other
89.77%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
170
35.06M
73.78%
-8.16M
2025Q1
155
37.71M
83.92%
-8.48M
2024Q4
145
40.31M
98.61%
+1.04M
2024Q3
142
37.92M
96.31%
-1.37M
2024Q2
139
36.35M
96.29%
-1.95M
2024Q1
131
36.78M
100.64%
+157.59K
2023Q4
124
35.04M
97.83%
-1.22M
2023Q3
117
35.82M
100.15%
-590.79K
2023Q2
111
36.00M
101.04%
+568.49K
2023Q1
103
35.28M
105.30%
-113.43K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Beryl Capital Management, LLC
--
0%
--
--
Amgen Inc
--
0%
--
--
Glazer Capital, LLC
--
0%
+498.61K
-100.00%
Oddo BHF Asset Management S.A.S
--
0%
+2.30M
-100.00%
Gabelli Funds, LLC
--
0%
+2.11M
-100.00%
VV Manager LLC
--
0%
-3.38M
-100.00%
683 Capital Management LLC
--
0%
-478.23K
-100.00%
The Vanguard Group, Inc.
--
0%
+212.12K
-100.00%
Alpine Associates Management Inc.
--
0%
+1.09M
-100.00%
Opaleye Management Inc.
--
0%
+1.00M
-100.00%
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
NYLI Merger Arbitrage ETF
0.21%
iShares Health Innovation Active ETF
0.1%
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
View more
NYLI Merger Arbitrage ETF
Proportion0.21%
iShares Health Innovation Active ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vigil Neuroscience Inc?
The top five shareholders of Vigil Neuroscience Inc are:
Beryl Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Amgen Inc holds 0.00 shares, accounting for 0.00% of the total shares.
Glazer Capital, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Oddo BHF Asset Management S.A.S holds 0.00 shares, accounting for 0.00% of the total shares.
Gabelli Funds, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Beryl Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Amgen Inc holds 0.00 shares, accounting for 0.00% of the total shares.
Glazer Capital, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Oddo BHF Asset Management S.A.S holds 0.00 shares, accounting for 0.00% of the total shares.
Gabelli Funds, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Vigil Neuroscience Inc?
The top three shareholder types of Vigil Neuroscience Inc are:
Beryl Capital Management, LLC
Amgen Inc
Glazer Capital, LLC
Beryl Capital Management, LLC
Amgen Inc
Glazer Capital, LLC
How many institutions hold shares of Vigil Neuroscience Inc (VIGL)?
As of 2025Q2, 170 institutions hold shares of Vigil Neuroscience Inc, with a combined market value of approximately 35.06M, accounting for 73.78% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -10.14%.
What is the biggest source of revenue for Vigil Neuroscience Inc?
In --, the -- business generated the highest revenue for Vigil Neuroscience Inc, amounting to -- and accounting for --% of total revenue.
